Related Experiment Video
Updated: Feb 11, 2026

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test
Published on: November 23, 2019
STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma
Haley M Simpson1,2,3, Aki Furusawa1,2,3, Kavitha Sadashivaiah1,2,3
1Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Abstract:
Peripheral T-cell lymphoma (PTCL) is a rare, aggressive, heterogeneous, Non-Hodgkin's lymphoma with poor prognosis and inadequate response to current therapies. Recent sequencing studies indicate a prevalence of activating mutations in the JAK/STAT signaling pathway. Oncogenic mutations in STAT5B, observed in approximately one third of cases of multiple different PTCL subtypes, correlate with inferior patient outcomes. Therefore, interest in the development of therapeutic strategies for targeting STAT5 in PTCL is warranted. In this study, we show that the drug pimozide inhibits STAT5 in PTCL, leading to apoptotic cell death by means of the TRAIL/DR4 dependent extrinsic apoptotic pathway. Pimozide induced PTCL cell death is caspase 8 dependent, increases the expression of the TRAIL receptor, DR4, on the surface of pre-apoptotic PTCL cells, and enhances TRAIL induced apoptosis in a TRAIL dependent manner. In parallel, we show that mRNA and protein levels of intrinsic pathway BCL-2 family members and mitochondrial membrane potential remain unaffected by STAT5 knockdown and/or inhibition. In primary PTCL patient samples, pimozide inhibits STAT5 activation and induces apoptosis. Our data support a role for STAT5 inhibition in PTCL and implicate potential utility for inhibition of STAT5 and activation of the extrinsic apoptotic pathway as combination therapy in PTCL.
Insights
The drug pimozide targets STAT5B mutations common in Peripheral T-cell lymphoma (PTCL), inducing cancer cell death via the TRAIL/DR4 pathway. This offers a potential new therapy for aggressive PTCL with poor prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Peripheral T-cell lymphoma (PTCL) is an aggressive non-Hodgkin's lymphoma with poor outcomes.
- Activating mutations in the JAK/STAT pathway, particularly STAT5B, are prevalent in PTCL and linked to worse prognosis.
- Targeting STAT5 represents a potential therapeutic strategy for PTCL.
Purpose of the Study:
- To investigate the efficacy of pimozide, a STAT5 inhibitor, in PTCL.
- To elucidate the mechanism of pimozide-induced cell death in PTCL.
Main Methods:
- Utilized PTCL cell lines and primary patient samples.
- Assessed the effect of pimozide on STAT5 activation, apoptosis, and the TRAIL/DR4 extrinsic pathway.
- Investigated the role of caspase 8 and TRAIL/DR4 in pimozide-mediated cell death.
- Examined the impact on intrinsic apoptotic pathway markers.
Main Results:
- Pimozide effectively inhibits STAT5 activation in PTCL cells and patient samples.
- Pimozide induces apoptotic cell death through the caspase 8-dependent TRAIL/DR4 extrinsic pathway.
- Pimozide increases DR4 expression and enhances TRAIL-induced apoptosis.
- The intrinsic apoptotic pathway and mitochondrial membrane potential were unaffected.
Conclusions:
- STAT5 inhibition is a viable strategy for PTCL treatment.
- Pimozide demonstrates therapeutic potential by activating the extrinsic apoptotic pathway.
- Combination therapy targeting STAT5 and the extrinsic apoptotic pathway may benefit PTCL patients.
More Related Videos
08:31Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
Related Concept Videos
Apoptosis
Feedback Inhibition
Frequency-dependent Selection
Enzyme Inhibition
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Induced Pluripotent Stem Cells